目的 探究腎復(fù)康膠囊聯(lián)合氫氯噻嗪片治療慢性腎小球腎炎的臨床療效。方法 選取2015年9月-2016年9月渭南市中心醫(yī)院腎內(nèi)科收治的慢性腎小球腎炎患者91例，隨機(jī)分成對照組（45例）和治療組（46例）。對照組口服氫氯噻嗪片，2片/次，3次/d。治療組在對照組基礎(chǔ)上口服腎復(fù)康膠囊，5粒/次，3次/d。兩組患者均治療6周。觀察兩組的臨床療效，比較兩組腎功能指標(biāo)和24 h尿蛋白定量的情況。結(jié)果 治療后，對照組和治療組的總有效率分別為82.22%、97.83%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組腎小球?yàn)V過率均顯著升高，而血清胱抑素C、尿素氮和血清肌酐水平均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療3、6周后，兩組24 h尿蛋白定量均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組同期24 h尿蛋白定量明顯低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 腎復(fù)康膠囊聯(lián)合氫氯噻嗪片治療慢性腎小球腎炎具有較好的臨床療效，能顯著改善腎功能，降低24 h尿蛋白定量，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Shenfukang Capsules combined with Hydrochlorothiazide Tablets in treatment of chronic glomerulonephritis. Methods Patients (91 cases) with chronic glomerulonephritis in Department of Endocrine of Weinan Central Hospital from September 2015 to September 2016 were randomly divided into the control group (45 cases) and the treatment group (46 cases). Patients in the control group were po administered with Hydrochlorothiazide Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Shenfukang Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacies were evaluated, and renal function and 24 h urinary protein content in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.22% and 97.83%, respectively, and there was difference between two groups (P<0.05). After treatment, the glomerular filtration rates in two groups were significantly increased, but the levels of serum cystatin C, urea nitrogen, and serum creatinine in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment for 3 and 6 weeks, 24 h urinary protein contents in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the 24 h urinary protein contents in the treatment group were significantly lower than that in the control group at the same time, with significant difference between two groups (P<0.05). Conclusion Shenfukang Capsules combined with Hydrochlorothiazide Tablets has clinical curative effect in treatment of chronic glomerulonephritis, can improve renal function, and decrease 24 h urinary protein contents, which has a certain clinical application value.